Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN): Is It The Ultimate Stock Picker’s Share?

LONDON — I use a market statistics to identify shares for further research. Whatever the market conditions, stock-picking software will always identify a share worth buying.

AstraZeneca plc (ADR) (NYSE:AZN) is the 12th biggest company in the FTSE 100. It is a true blue chip. According to a large number of investment strategies, the shares should be bought today.

What’s to love?
AstraZeneca shares satisfy selection criteria that makes them attractive to three different types of investor. AstraZeneca currently ticks the boxes for value, income, and momentum strategies.

A value play
Investors have long been skeptical of the company’s ability to develop new drugs. Perhaps as a result of this, AstraZeneca plc (ADR) (NYSE:AZN) shares made no progress at all in the three years ending 2012.

AstraZeneca plc (ADR) (NYSE:AZN)Today, AstraZeneca trades on a 2013 P/E of just 9.6 times 2013 forecasts. AstraZeneca’s rating is in the bottom 10% of the entire index. Low valuations like that are usually the result of masses of negative sentiment.

If AstraZeneca can convince the markets that its earnings are not about to enter a prolonged decline, then I would expect the shares to rise significantly.

Income credentials
According to the consensus of broker forecasts, AstraZeneca plc (ADR) (NYSE:AZN) trades on a prospective yield for 2013 of 5.5%. The 2014 forecast dividend yield amounts to an impressive 5.6%. The payout is almost twice covered by earnings, meaning that there is little risk of a cut.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.